Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Thomas

Showing results (91-100 of 155) with videos related to

Pageof 16
Sort By:
Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Cancer|January 28, 2004
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapyGloria N Mattiuzzi, Hagop Kantarjian, Stefan Faderl, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Phase I study of bortezomib in refractory or relapsed acute leukemiasJorge Cortes, Deborah Thomas, Charles Koller, et al.
Blood|April 9, 2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|October 14, 2004
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Susan O'Brien, et al.
Inflammatory Bowel Diseases|August 22, 2025
Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseasesScott R Anderson, Ali Osman, Mohammad Zamani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Pageof 16

Showing results (91-100 of 155) with videos related to

Sort By:
Pageof 16
Haematologica|February 16, 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNaval Daver, Deborah Thomas, Farhad Ravandi, et al.
British Journal of Haematology|January 17, 2007
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemiaFrancis J Giles, Gautam Borthakur, Farhad Ravandi, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Cancer|January 28, 2004
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapyGloria N Mattiuzzi, Hagop Kantarjian, Stefan Faderl, et al.
Cancer|May 2, 2013
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2004
Phase I study of bortezomib in refractory or relapsed acute leukemiasJorge Cortes, Deborah Thomas, Charles Koller, et al.
Blood|April 9, 2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cancer|October 14, 2004
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaHagop Kantarjian, Deborah Thomas, Susan O'Brien, et al.
Inflammatory Bowel Diseases|August 22, 2025
Systematic Review With Meta-Analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseasesScott R Anderson, Ali Osman, Mohammad Zamani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignanciesKaren W L Yee, Zhihong Zeng, Marina Konopleva, et al.
Pageof 16